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Abstract
Background: Hirschsprung disease is characterized by the absence of intramural ganglion cells in the enteric plexuses, 
due to a fail during enteric nervous system formation. Hirschsprung has a complex genetic aetiology and mutations in 
several genes have been related to the disease. There is a clear predominance of missense/nonsense mutations in 
these genes whereas copy number variations (CNVs) have been seldom described, probably due to the limitations of 
conventional techniques usually employed for mutational analysis. In this study, we have looked for CNVs in some of 
the genes related to Hirschsprung (EDNRB, GFRA1, NRTN and PHOX2B) using the Multiple Ligation-dependent Probe 
Amplification (MLPA) approach.
Methods: CNVs screening was performed in 208 HSCR patients using a self-designed set of MLPA probes, covering the 
coding region of those genes.
Results: A deletion comprising the first 4 exons in GFRA1 gene was detected in 2 sporadic HSCR patients and in silico 
approaches have shown that the critical translation initiation signal in the mutant gene was abolished. In this study, we 
have been able to validate the reliability of this technique for CNVs screening in HSCR.
Conclusions: The implemented MLPA based technique presented here allows CNV analysis of genes involved in HSCR 
that have not been not previously evaluated. Our results indicate that CNVs could be implicated in the pathogenesis of 
HSCR, although they seem to be an uncommon molecular cause of HSCR.
Background
Hirschsprung disease (HSCR, OMIM 142623) is a con-
genital malformation characterized by the absence of
intramural ganglion cells in the myenteric and submu-
cosal plexuses along a variable portion of the distal intes-
tine, due to a defect of craniocaudal migration of
neuroblasts originated from the neural crest [1,2]. HSCR
presents an estimated incidence of 1/5000 live births, and
has a non mendelian inheritance with reduced pene-
trance, variable expression and male predominance.
Although familial forms exist, the vast majority of cases
are sporadic. In addition, the disease can present as an
isolated trait, although in a 30% of the cases it is associ-
ated with chromosomal abnormalities, neurodevelop-
ment disorders and a variety of additional isolated
anomalies and syndromes [2].
HSCR has a complex genetic aetiology with several
genes being described as associated with isolated or syn-
dromic forms. RET  proto-oncogene is considered the
m a j o r  c a u s a l  g e n e  i n  H S C R  a n d  h a s  b e e n  e x t e n s i v e l y
studied in different HSCR series worldwide. Both tradi-
tional RET coding mutations and a common non-coding
RET variant within a conserved enhancer-like sequence
in intron 1, have been reported to be associated with a
great proportion of HSCR cases [2-4]. Other genes asso-
cia t ed wit h HSCR  e nc ode  f o r r ec ep t o rs,  liga nds  ( es pe -
cially those participating in the RET  and  EDNRB
signaling transduction pathways), and transcriptional fac-
tors, such as SOX10 and PHOX2B, among others, that are
usually involved in the neural crest cell development and
migration [2].
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Interestingly, many recent reports point out the impli-
cations of altered gene dosage in diagnosis, prognosis and
therapy in different human diseases [5]. Nonetheless, it
does not seem to be apparently the case of HSCR, with
the current data supporting a predominance of missense/
nonsense mutations, although small deletions/insertions
have been occasionally observed (Human Gene Mutation
Database of the Institute of Medical Genetics in Cardiff,
http://www.hgmd.cf.ac.uk/ac/index.php). In fact, no
duplications and only one gross deletion affecting the
entire sequence of RET have been reported [6,7]. To date,
only 2 studies have been reported investigating gene dos-
ages anomalies in HSCR patients based on MLPA tech-
nique (Multiple Ligation-dependent Probe
Amplification) [8,9], which has an optimal performance
to detect alterations of gene dosages [10]. Both of them
used MLPA MRC-Holland commercial kit for HSCR,
that analyses a limited number of genes (RET, ZEB2,
EDN3 and GDNF), and revealed no CNVs associated to
HSCR in those genes [8,9]. In additions we have per-
formed a SOX10  deletion screening on our HSCR
patients [11] based on a previously reported QMF-PCR
method (Quantitative Multiplex Fluorescent PCR),
obtaining negative results [12]. Nevertheless, studies in
other "HSCR genes" are necessary to rule out the poten-
tial implication CNVs in the pathogenesis of HSCR.
In the present study we have analyzed the presence of
CNVs for EDNRB, NRTN, GFRA1 and PHOX2B in our
patient series, using self-designed MLPA probes, as no
commercial kit is available for those genes, and none of
them has been previously evaluated for mid-size dele-
tions/duplications using a high-throughput technique.
The present self-design set of probes for MLPA analysis,
together with the available MLPA commercial kit for
HSCR, would lead to the complete analysis of CNVs
within coding region of the most prevalent genes in
HSCR.
Methods
Patients and Control Subjects
In this study, a total of 208 HSCR patients have been
included (22% female, 77% male). 188 out of the 208
patients were sporadic cases, while 20 were familial cases
belonging to 13 different families. In addition, 6 of those
patients presented with associated Down's syndrome, and
1 presented with Waarbenburg's Syndrome type 4. In
order to define the exact HSCR phenotype in our
patients, we have used the criteria recommended by
Chakravarti and Lyonnett [1]. Following these criteria,
137 cases were catalogued as short-segment HSCR (S-
HSCR, 81%), 21 cases as long-segment (L-HSCR, 12%),
and 12 cases presented as total colonic aganglionosis
(TCA, 7%). Data were not available for the remaining 38
cases.
We have also used a group of 100 controls comprising
unselected, unrelated, race, age, and sex-matched indi-
viduals. All of them were healthy voluntary donors, who
came to the Hospital for other reasons and did not pres-
ent any symptom suggestive of HSCR.
Genomic DNA was extracted according to standard
protocols and an informed consent was obtained from all
the participants for clinical and molecular genetic stud-
ies. The study conformed to the tenets of the declaration
of Helsinki and was approved by the Hospitales Universi-
tarios Virgen del Rocío IRB.
MLPA analysis
Gene dosage variations on EDNRB, GFRA1, NRTN and
PHOX2B were analysed by MLPA technology. The selec-
tion of the genes was based on their implication in ENS
development and HSCR disease [13]. More specifically,
we have selected EDNRB, the second major gene for
HSCR, which has a considerably higher mutational inci-
dence than EDN3, GDNF or ZEB2 [2], included in the
commercial kit. Since RET  and  GDNF  are already
included in the commercial MLPA kit for HSCR, we
decided to include NRTN and GFRA1, as they are impli-
cated in the same signaling pathway and have been previ-
ously associated to HSCR [14,15]. In addition and due to
the implication of PHOX2B deletions in human patholo-
gies and syndromes than frequently present with HSCR
(CCHS) [16], we have also included this gene in the pres-
ent study. Following MRC-Holland recommendations, we
designed 31 sets of probes to detect deletions and dupli-
cations in one or more exons of these 4 genes (Table 1). In
addition, we designed 3 control fragments hybridizing to
different genome regions, that have never been associ-
ated with HSCR before and have been reported to con-
ta in no CNV s.  Pr obes a nd EK -1 kits  we r e  s upp lied by
Sigma (Sigma-Aldrich, St. Louise, MO) and MRC-Hol-
land (MRC-Holland, Amsterdam, Netherlands) respec-
tively.
Capillary electrophoresis analysis was performed using
an ABI PRISM® 3730 DNA analyzer (Applied Biosystems,
Foster City, CA) and for data analysis we used Gene-
Marker v 1.75 (Softgenetics L.L.C, State College, PA). We
normalized the samples by peak height comparing
patients with 10 controls. These 10 control individuals
had been confirmed to have no duplications or deletions
in the studied genes, by a previous analysis using Affyme-
trix Genome-Wide Human SNP Arrays 6.0. In addition as
a positive control we included a patient harbouring a
GFRA1 deletion in heterozygosis (patient HSCR-5, pre-
senting with TCA-total colonic aganglionosis), which had
been previously characterized by southern blot and lost
of heterozygosity of STRs [15]. This individual not only
was useful as positive control, but also confirmed the
validity of our method to detect deletions in the genesSánchez-Mejías et al. BMC Medical Genetics 2010, 11:71
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Table 1: Self-designed MLPA probes used in the molecular analysis of EDNRB, GFRa1, NRTN and PHOX2B CNVs of 208 HSCR 
patients.
Exon Probe Oligo Sequence* bp
EDNRB EDNRBen1Δ3 LPO TCTGGCGGTGATTGATGGGAAG 100
RPO GGATGAATGAATAAAAGTACTTGTCTGATGGCACCC
EDNRBex1 LPO TCTACAAGAACAAGTGCATGCGAAACG 112
RPO GTCCCAATATCTTGATCGCCAGCTTGCCATCAATCGCCATTCGA
EDNRBex2 LPO GGCAGAGGACTGGCCATTTGGAG 90
RPO CTGAGATGTGTAAGCTGGTGCCTTT
EDNRBex3 LPO CGACAGCAGTAGAAATTGTTTTGATTTGGGTG 128
RPO  GTCTCTGTGGTTCTGGCTGTCCCTGAAGAGGTT 
TTGTGTACGGACCTAAAGTTC
EDNRBex4 LPO TGGCATGCAGATTGCTTTAAATGATCAC 113
RPO CTAAAGCAGGTAAGAAAATACAAATATTGAGAGGGACACGGCG
EDNRBex5 LPO GTGGCCAAAACCGTCTTTTGCCTG 93
RPO GTCCTTGTCTTTGCCCTCTGCTGGCTT
EDNRBex6 LPO CGATGCTATTCACATAACCCAATTGCTCTGTATTTGGTGAG 130
RPO GTGAGCAAAAGATTCAAAAACTGCTCTTGGAGGAAGTCGAGGAGTAC
EDNRBex7 LPO GCAGTCGTGCTTAAAGTTCAAAG 99
RPO CTAATGATCACGGATATGACAACTTTGCTGAGTG
GFRα1 GFRa1ex1 LPO CCTAGCGCAGATAAAGTGAGCCCGGAAAG 135
RPO GGAAGGAGGGGGCGGGGACACCATTGCTATAGA 
CGTAGCTGTGAGTACCAACCGAATAGCAATC
GFRa1ex2 LPO CAACGACTAGAGAGGCACCATGTTCCTGGCGACC 127
RPO GATGGAGCTGAACTTTGGGCGGCCAGTGACT 
GCCTTGAAGGTCTCACGGCT
GFRa1ex3 LPO GGAGAAGAACTGCCTGCGCATTTACTGGAG 96
RPO CATGTACCAGAGCCTGCAGGGTAC
GFRa1ex4 LPO GGAGGATTCCCCATATGAACCAGTTAACAG 100
RPO CAGATTGTCAGATATATTCCGGGTGGTC
GFRa1ex5 LPO CAGGCACTTGAGGATTTCCCAGGTAGGACCCTCTAGTTGCAG 131
RPO GAAAACAAGGTCAGGGCTGCCACTGGTTCTATAATACAATGGAGACG
GFRa1ex6 LPO GGAACAACTGCCTGGATGCAGCGAAGGCCTG 108
RPO CAACCTCGACGACATTTGCAAGAAGTACCCGGTAT
GFRa1ex7 LPO TGCCAGCCAGAGTCAAGGTCTGTCAG 95
RPO CAGCTGTCTAAAGGAAAACTACGCTGA
GFRa1ex8 LPO CCATACATCACCGCATTCTCGCAGAAGAGCCTC 
AGTGTGGCCCCATGGTGTGACTG
132
RPO CAGCAACAGTGGGAACGACCTAGAAGAGTGCTTG
GFRa1ex9a LPO GAGGAAGTTCAATGGCTCCGATGTGACCGTGTGGCAG 108
RPO CCAGCCTTCCCAGTACAGACCACCACTGC
GFRa1ex9b LPO CCAATTGACCACCTATGGGCCCAGTCC 140
RPO CCAGTCAGGTCAAAGAAGAGGGTTTACGTAGACCTCA 
GTTCACTGGAGTCTGTCGTTTGCTCTATACTCAC
GFRa1ex9c LPO GGTTCAGGCAACACAGAGACAAAG 91
RPO CATCTTCAGGGGGAGCAGGTAGAGGSánchez-Mejías et al. BMC Medical Genetics 2010, 11:71
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GFRa1ex9d LPO GTGTCCACTTGTTTTACGCAG 108
RPO CTGACTTTACTGGACATTATTCAGACCAGTGGTTGGGTGCGCTCG
GFRa1ex10 LPO GCTGAAATCCAATGTGTCGGGCAATACACAC 112
RPO CTCTGTATTTCCAATGTAAGTATGGGCGTGGACTCGCAT
GFRa1ex11 LPO  CCAAACTGTGCGCGTGTCGATAAGGTTCCGTTCCCG 
CCCACTGCTGGTCCTGGTGGTAACC
136
RPO GCTCTGTCCACCCTATTATCTTTAACAGAAACA
NRTN NRTNex1 LPO CGTTCAAAGTCAAAGGCCCCACACTGAGTC 136
RPO CTGGCCCAGCGCCCTGTGCCCGTTGGCTGACGA 
GAAGTACGGAATCGAATCTATAGTGACCTAT
NRTNex2 LPO CGAATTAGAGATTTAACTTCCTCCCCTCGCAGACCGTGCACTC 139
RPO CTGCAGGGGGCCCCGGATGCGATGGAGCTGTTAA 
TACGACTCACTATAGGAGTA
PHOX2B PHOX2B5'UTR LPO CTTAAATCATGGGGCCACTGAAGTC 92
RPO CACACACTGCTCGCTCCTTTGT
PHOX2Bex1A LPO CCTCAATTCCTCTGCCTACGAGTC 88
RPO CTGTATGGCTGGGATGGACACC
PHOX2Bex1B LPO CCAGTGGCTTCCAGTATAACCCGATAAGGAC 96
RPO CACTTTTGGGGCCACGTCCGGCT
PHOX2Bex2 LPO CTGTCATACTCTAGTTCCTTACAAACTCTTCAC 108
RPO GGACCACGGCGGCCTCAACGATGCAAGCGACAT
PHOX2Bex3A LPO TCTTCTTTCTCCCCCTGCTTCACCGTCTCTC 112
RPO CTTCCGTCTTGGGCCAGGTGTGGTTCCAGAATTTACTAA
PHOX2Bex3B LPO CGTCCTATCTTCGCTCCAAAGACCCAACG 100
RPO GTGCCAAAGCCGCCTTAGTGAAGAGCAGT
PHOX2B3'UTR LPO CTTTTTCATTGAGGGCCTAAAGTAATCGCGCTAAGAATAAAG 126
RPO GGAAAACGGCGTCGCCCTCATTTGCAAACTGTGCGGGTGTCG
Reference genes TOR1A LPO GCACCGGCAAAAATTTCGTCAGCAAGATCAT 104
RPO CGCAGAGAATATTTACGAGGGTGGTCTGAAC
EPO LPO GCCTCAGCTGCTCCACTCCGAACAATCACTG 117
RPO CTGACACTTTCCGCAAACTCTTCCGAGTCTAGATAGTTCCAACAA
SS18 LPO CGACAGCATTACGAAGCACAGCAGCCACCTATGGGAATGATG 122
RPO GGTCAAGTTAACCAAGGCAATCATATGATGCGATATGC
*Sequences do not included the universal primers located al the 5' end of LPO and 3' end of RPO.
Table 1: Self-designed MLPA probes used in the molecular analysis of EDNRB, GFRa1, NRTN and PHOX2B CNVs of 208 HSCR 
patients. (Continued)
analysed. Following manufacturer recommendations,
dosage quotients under 0.5 or over 1.3 were considered as
indicating potential deletions or duplications respec-
tively, and were confirmed in 3 independent assays.
Results
With the aim to analyse anomalies in the gene dosage of
several genes described as associated to HSCR (EDNRB,
GFRA1, NRTN and PHOX2B), but never previously ana-
lyzed by MLPA, we designed specific synthetic MLPA D-
probes, following MRC-Holland recommendations. The
hybridization, ligation and amplification of the MLPA
probes were performed in 4 different probemixes of 8-10
probes each, together with the 3 control probes. Signal
peaks height of the amplified products observed after
e l e c t r o p h o r e s i s ,  w e r e  a s  h o m o g e n e o u s  a s  e x p e c t e d  f o r
self-designed probes, and peak normalization was suc-Sánchez-Mejías et al. BMC Medical Genetics 2010, 11:71
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cessfully fulfilled between the patient samples and con-
trols in all the probemixes tested.
After the validation of our probes, we screened a total
of 208 HSCR patients and found a deletion in GFRA1
gene (c.(?-555)_431+?del; Figure 1) that affects exons 1a,
2a, 3 and 4 in isoform NM_005264 and exons 2b, 3 and 4
in isoform NM_145793. This deletion was detected in a
heterozygous state, in a sporadic and isolated male HSCR
patient presenting with short-segment HSCR (patient
HSCR-115), and was not found in 100 control individuals
tested. This deletion was inherited by his unaffected
father, and was found to be absent in other healthy mem-
bers of the family. There are 2 CNVs described for
GFRA1  gene annotated in the Database of Genomics
Variants http://projects.tcag.ca, Variant_48418 and
Variant_48004. The first variant is a 2.5Kb deletion
located in the 3' untranslated region of the gene, while the
other consisted on a 36 Kb deletion the genomic region
containing exons 7, 8 and 9 of GFRA1. Therefore, the
available data support that we are describing a novel dele-
tion. Interestingly, this is the second time this deletion
has been found in our HSCR patient series, in a patient
not related with the one previously reported [Figure 1;
15].
In order to preliminarily examine the potential damag-
ing effect of this deletion on GFRA1 expression and func-
tionality, we used InterProScan and AlternativeSplicing
tools from EBI and Transec from EMBOSS. We verified
that the critical translation initiation signal in the gene
was abolished; subsequently no wild-type (WT) protein
was expected to be expressed from the deleted copy of
the gene. In adition, we checked in silico whether the
deleted allele could produce any protein with similar
functional capacity as GFRα1. We found that an alterna-
tive peptide could be translated from deleted isoform
NM_005264 with the same carboxyl-terminus amino-
acidic sequence. This putative protein would maintain
one of the 3 GDNF/GAS1 domains in the WT protein,
but would also lack the localization signal in the N-termi-
nal region. Although this deletion is well refined in its 3'
end, we failed to establish the boundaries in the 5' end
where all transcription and translation signals are
located. Therefore it seems unlikely that the aberrant
protein could be expressed, and in that case it would have
a very limited, or even null, functionality.
Discussion
HSCR has a complex genetic aetiology and point muta-
tions in several genes have been reported to be implicated
in a portion of isolated and syndromic HSCR forms [2]. It
is tempting to speculate that other genetic events differ-
ent from point mutation, such as CNVs, have a functional
role in the pathogenesis of HSCR. Very little is known in
this field for HSCR since typical screening methods based
in conventional PCR are only able to detect small dele-
tions/duplications (a few base pairs), and cytogenetic
techniques can exclusively detect alterations in the order
of megabases. Those techniques are neither powerful nor
adequate to detect CNVs [10], so that those types of rear-
rangements would be missed. In this way, it would be
possible that such mid-size deletions/duplications in sev-
eral HSCR genes have been underreported. In addition,
traditional techniques used to detect mid-size deletions/
duplications, such as southern blot, are expensive, time
consuming and not suitable for high-throughput results.
For this reason we planned to perform CNVs screening in
a large series of HSCR patients using MLPA technology,
which can be performed in a large number of individuals
within a short period time, in order to determine if it is a
reliable technique suitable for a routine CNVs screening.
Despite the negative results previously reported for
HSCR MLPA commercial kit [8,9], we have obtained pos-
itive results with the finding of a deletion affecting the 4
first exons in GFRA1. This deletion was previously identi-
fied in a sporadic HSCR patient, but its actual implication
in the pathogenesis of this disease remained unknown
[15]. The finding of the same deletion in an independent
patient with the same phenotype and its absence in the
control population, support that this deletion at the
GFRA1 locus is a mutational event potentially related to
HSCR. In addition, the implementation of MLPA tech-
nique for midsize deletion detection leads us to refine the
deleted region at GFRA1 locus. The protein GFRα1 is one
of the four co-receptors of the RET tyrosine kinase recep-
tor. The binding of RET to GFRα1 is required for the spe-
cific recruitment of GDNF and the subsequent
phosphorylation of RET. Therefore, the presence of such
a deletion in GFRα1 would avoid the expression of the
protein, presumably preventing RET phosphorylation
and affecting the correct development of the ENS. The
presence of this mutation in unaffected members of the
family suggest that it could be necessary but not sufficient
to produce the phenotype, and additional unidentified
genetic events might be acting in this HSCR patient. In
this sense, no point coding mutations were detected in
this patient, or in the previously described patient har-
bouring the same deletion, in other HSCR-related genes
tested such as RET, GDNF, NRTN, PSPN, ARTN, EDNRB,
EDN3, NTF3, NTRK3, SOX10 or PHOX2B. The present
results indicate that CNVs are not a common molecular
c a u s e  o f  H S C R ,  a l t h o u g h  t h e y  s h o u l d  b e  t a k e n  i n t o
account for further studies.
Conclutions
One of our goals was to provide a simple, reliable, eco-
nomic and fast method for CNVs screening in HSCR
related genes, and the present study has successfully vali-
dated the self-designed MPLA probes for CNVs analysis.Sánchez-Mejías et al. BMC Medical Genetics 2010, 11:71
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The design and validation of MLPA probes for additional
genes represent an implementation for a technique that
was restricted to the commercial production. In this
sense, the present design, together with the commercial
MLPA kit for HSCR, allows the complete analysis of
CNVs in the coding region of the most prevalent genes
for HSCR. In addition, the presence of a GFRA1 deletion
that seems to impair protein function, in an unrelated
HSCR patient supports and confirms the idea that this
specific deletion might participate in the development of
HSCR. Despite the fact that CNVs seems to be an
uncommon susceptibility factor leading to this disease,
our results point out the importance of taking into
account those molecular events in HSCR studies from
now on, at least in GFRA1  gene. Further screening of
CNVs in additional series of patients would be necessary
in order to completely address its real implications in the
pathogenesis of HSCR.
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